Cellectis Plans Clinical Trial to Test Donor-derived CAR T-cell Therapy, Possible Multiple Myeloma Treatment
Cellectis announced plans to open a Phase 1 clinical trial to evaluate UCARTCS1 — its first allogeneic (donor-derived) CAR T-cell therapy for multiple myeloma patients —…